Clinical Trials Directory

Trials / Completed

CompletedNCT00060957

Botulinum Toxin (BOTOX) for Cerebral Palsy

Botulinum Toxin for Spasticity in Cerebral Palsy

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
40 (planned)
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · NIH
Sex
All
Age
3 Years – 12 Years
Healthy volunteers
Not accepted

Summary

This study examines botulinum toxin (BOTOX, or BTX) for the treatment of muscle twitches and spasticity associated with cerebral palsy in children. Botulinum toxin is a naturally occurring bacterial toxin (botulinum toxin) that inactivates certain parts of muscles.

Detailed description

This trial will test the effectiveness of BTX injections versus placebo to reduce plantar-flexor spasticity and improve function and mobility in children with spastic diplegia, a common form of cerebral palsy. The study will evaluate the effects of the treatment across five domains that relate to disability: pathophysiology, impairment, functional limitation, disability, and societal limitation. Forty children, ages 4 to 12 years, will be recruited and randomized into one of two groups. Group A will receive BTX. Group B will receive a placebo injection. Participants will be assessed at the beginning of the trial and at Weeks 3, 8, 12, and 24. Assessments include quantitative electromyographic kinesiology measurements, electromechanical measurement of joint torque across the ankle joint using the Spasticity Measurement System, Gross Motor Function Measure, physical exam parameters, energy expenditure using the Energy Cost Index, kinematic gait analysis, and the Canadian Occupational Performance Measure. Participants are followed for a total of 6 months. Participants initially randomized to Group B will have the opportunity for BTX treatment after 24 weeks.

Conditions

Interventions

TypeNameDescription
DRUGBotulinum toxin type A

Timeline

Start date
1997-07-01
Primary completion
2002-06-01
First posted
2003-05-19
Last updated
2016-09-26

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00060957. Inclusion in this directory is not an endorsement.